Research ExplorerPublicationsTreatment of pathophysiologic propagation outside of the pul...

Treatment of pathophysiologic propagation outside of the pulmonary veins in retreatment of atrial fibrillation patients: RECOVER AF study

Standard

Treatment of pathophysiologic propagation outside of the pulmonary veins in retreatment of atrial fibrillation patients: RECOVER AF study. / Betts, Timothy R; Good, Wilson W; Melki, Lea; Metzner, Andreas; Grace, Andrew; Verma, Atul; Murray, Stephen; James, Simon; Wong, Tom; Boersma, Lucas V A; Steven, Daniel; Sultan, Arian; Busch, Sonia; Neužil, Petr; de Asmundis, Carlo; Lee, Justin; Szili-Török, Tamás.

In: EUROPACE, Vol. 25, No. 5, euad097, 19.05.2023.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Betts, TR, Good, WW, Melki, L, Metzner, A, Grace, A, Verma, A, Murray, S, James, S, Wong, T, Boersma, LVA, Steven, D, Sultan, A, Busch, S, Neužil, P, de Asmundis, C, Lee, J & Szili-Török, T 2023, 'Treatment of pathophysiologic propagation outside of the pulmonary veins in retreatment of atrial fibrillation patients: RECOVER AF study', EUROPACE, vol. 25, no. 5, euad097. https://doi.org/10.1093/europace/euad097

APA

Betts, T. R., Good, W. W., Melki, L., Metzner, A., Grace, A., Verma, A., Murray, S., James, S., Wong, T., Boersma, L. V. A., Steven, D., Sultan, A., Busch, S., Neužil, P., de Asmundis, C., Lee, J., & Szili-Török, T. (2023). Treatment of pathophysiologic propagation outside of the pulmonary veins in retreatment of atrial fibrillation patients: RECOVER AF study. EUROPACE, 25(5), [euad097]. https://doi.org/10.1093/europace/euad097

Vancouver

Betts TR, Good WW, Melki L, Metzner A, Grace A, Verma A et al. Treatment of pathophysiologic propagation outside of the pulmonary veins in retreatment of atrial fibrillation patients: RECOVER AF study. EUROPACE. 2023 May 19;25(5). euad097. https://doi.org/10.1093/europace/euad097

Bibtex

@article{a4325a3482094c2f95ef91ddbd2e51fe,
title = "Treatment of pathophysiologic propagation outside of the pulmonary veins in retreatment of atrial fibrillation patients: RECOVER AF study",
abstract = "AIMS: RECOVER AF evaluated the performance of whole-chamber non-contact charge-density mapping to guide the ablation of non-pulmonary vein (PV) targets in persistent atrial fibrillation (AF) patients following either a first or second failed procedure.METHODS AND RESULTS: RECOVER AF was a prospective, non-randomized trial that enrolled patients scheduled for a first or second ablation retreatment for recurrent AF. The PVs were assessed and re-isolated if necessary. The AF maps were used to guide the ablation of non-PV targets through elimination of pathologic conduction patterns (PCPs). Primary endpoint was freedom from AF on or off antiarrhythmic drugs (AADs) at 12 months. Patients undergoing retreatment with the AcQMap System (n = 103) were 76% AF-free at 12 months [67% after single procedure (SP)] on or off AADs (80% free from AF on AADs). Patients who had only received a pulmonary vein isolation (PVI) prior to study treatment of non-PV targets with the AcQMap System were 91% AF-free at 12 months (83% SP). No major adverse events were reported.CONCLUSION: Non-contact mapping can be used to target and guide the ablation of PCPs beyond the PVs in persistent AF patients returning for a first or second retreatment with 76% freedom from AF at 12 months. The AF freedom was particularly high, 91% (43/47), for patients enrolled having only a prior de novo PVI, and freedom from all atrial arrhythmias for this cohort was 74% (35/47). These early results are encouraging and suggest that guiding individualized targeted ablation of PCPs may therefore be advantageous to target at the earliest opportunity in patients with persistent AF.",
keywords = "Humans, Atrial Fibrillation/diagnosis, Prospective Studies, Pulmonary Veins/surgery, Retreatment, Anti-Arrhythmia Agents, Catheter Ablation/adverse effects, Treatment Outcome, Recurrence",
author = "Betts, {Timothy R} and Good, {Wilson W} and Lea Melki and Andreas Metzner and Andrew Grace and Atul Verma and Stephen Murray and Simon James and Tom Wong and Boersma, {Lucas V A} and Daniel Steven and Arian Sultan and Sonia Busch and Petr Neu{\v z}il and {de Asmundis}, Carlo and Justin Lee and Tam{\'a}s Szili-T{\"o}r{\"o}k",
note = "{\textcopyright} The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology.",
year = "2023",
month = may,
day = "19",
doi = "10.1093/europace/euad097",
language = "English",
volume = "25",
journal = "EUROPACE",
issn = "1099-5129",
publisher = "Oxford University Press",
number = "5",

}

RIS

TY - JOUR

T1 - Treatment of pathophysiologic propagation outside of the pulmonary veins in retreatment of atrial fibrillation patients: RECOVER AF study

AU - Betts, Timothy R

AU - Good, Wilson W

AU - Melki, Lea

AU - Metzner, Andreas

AU - Grace, Andrew

AU - Verma, Atul

AU - Murray, Stephen

AU - James, Simon

AU - Wong, Tom

AU - Boersma, Lucas V A

AU - Steven, Daniel

AU - Sultan, Arian

AU - Busch, Sonia

AU - Neužil, Petr

AU - de Asmundis, Carlo

AU - Lee, Justin

AU - Szili-Török, Tamás

N1 - © The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology.

PY - 2023/5/19

Y1 - 2023/5/19

N2 - AIMS: RECOVER AF evaluated the performance of whole-chamber non-contact charge-density mapping to guide the ablation of non-pulmonary vein (PV) targets in persistent atrial fibrillation (AF) patients following either a first or second failed procedure.METHODS AND RESULTS: RECOVER AF was a prospective, non-randomized trial that enrolled patients scheduled for a first or second ablation retreatment for recurrent AF. The PVs were assessed and re-isolated if necessary. The AF maps were used to guide the ablation of non-PV targets through elimination of pathologic conduction patterns (PCPs). Primary endpoint was freedom from AF on or off antiarrhythmic drugs (AADs) at 12 months. Patients undergoing retreatment with the AcQMap System (n = 103) were 76% AF-free at 12 months [67% after single procedure (SP)] on or off AADs (80% free from AF on AADs). Patients who had only received a pulmonary vein isolation (PVI) prior to study treatment of non-PV targets with the AcQMap System were 91% AF-free at 12 months (83% SP). No major adverse events were reported.CONCLUSION: Non-contact mapping can be used to target and guide the ablation of PCPs beyond the PVs in persistent AF patients returning for a first or second retreatment with 76% freedom from AF at 12 months. The AF freedom was particularly high, 91% (43/47), for patients enrolled having only a prior de novo PVI, and freedom from all atrial arrhythmias for this cohort was 74% (35/47). These early results are encouraging and suggest that guiding individualized targeted ablation of PCPs may therefore be advantageous to target at the earliest opportunity in patients with persistent AF.

AB - AIMS: RECOVER AF evaluated the performance of whole-chamber non-contact charge-density mapping to guide the ablation of non-pulmonary vein (PV) targets in persistent atrial fibrillation (AF) patients following either a first or second failed procedure.METHODS AND RESULTS: RECOVER AF was a prospective, non-randomized trial that enrolled patients scheduled for a first or second ablation retreatment for recurrent AF. The PVs were assessed and re-isolated if necessary. The AF maps were used to guide the ablation of non-PV targets through elimination of pathologic conduction patterns (PCPs). Primary endpoint was freedom from AF on or off antiarrhythmic drugs (AADs) at 12 months. Patients undergoing retreatment with the AcQMap System (n = 103) were 76% AF-free at 12 months [67% after single procedure (SP)] on or off AADs (80% free from AF on AADs). Patients who had only received a pulmonary vein isolation (PVI) prior to study treatment of non-PV targets with the AcQMap System were 91% AF-free at 12 months (83% SP). No major adverse events were reported.CONCLUSION: Non-contact mapping can be used to target and guide the ablation of PCPs beyond the PVs in persistent AF patients returning for a first or second retreatment with 76% freedom from AF at 12 months. The AF freedom was particularly high, 91% (43/47), for patients enrolled having only a prior de novo PVI, and freedom from all atrial arrhythmias for this cohort was 74% (35/47). These early results are encouraging and suggest that guiding individualized targeted ablation of PCPs may therefore be advantageous to target at the earliest opportunity in patients with persistent AF.

KW - Humans

KW - Atrial Fibrillation/diagnosis

KW - Prospective Studies

KW - Pulmonary Veins/surgery

KW - Retreatment

KW - Anti-Arrhythmia Agents

KW - Catheter Ablation/adverse effects

KW - Treatment Outcome

KW - Recurrence

U2 - 10.1093/europace/euad097

DO - 10.1093/europace/euad097

M3 - SCORING: Journal article

C2 - 37072340

VL - 25

JO - EUROPACE

JF - EUROPACE

SN - 1099-5129

IS - 5

M1 - euad097

ER -